Regeneron Pharmaceuticals, Inc. stock price

Regeneron Pharmaceuticals, Inc. latest news:


  • 01/08/2018 09:41:17

    Health-care ETF tumbles as biotechnology stocks weigh

    The largest exchange-traded fund to track the health-care sector fell on Monday, dropping as the biggest declining industry of the day by far. The Health Care Select Sector SPDR ETF was down 0.8%, its biggest one-day percentage drop since Dec. 14. The fund is coming off a four-day rally, and it hit a record on Friday. Biotechnology companies were the biggest drags on the sector on Monday. Celgene Corp. fell 3.2% after it agreed to buy blood-disease biotechnology company Impact Biomedicines for as much as $7 billion. Separately, Biogen Inc. shares fell 3.9% while those for Regeneron Pharmaceuticals was down 3.1%. The iShares Nasdaq Biotechnology ETF fell 0.8% on Monday. Thus far this year, the health-care fund is up 2.3%, compared with the 2.6% rise of the S&P 500 . The S&P was unchanged in Monday trading.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/03/2018 15:40:41

    Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

    Jan 3 (Reuters) - Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

  • 12/13/2017 18:45:00

    Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

    An immuno-oncology drug that's in the works could generate significant revenue growth someday.

  • 12/12/2017 23:04:51

    BRIEF-Regeneron And Sanofi Announce Positive Topline Pivotal Results For Pd-1 Antibody Cemiplimab In Advanced Cutaneous ...

    Regeneron Pharmaceuticals Inc(REGN): * REGENERON AND SANOFI ANNOUNCE POSITIVE TOPLINE PIVOTAL RESULTS FOR PD-1 ANTIBODY CEMIPLIMAB IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA. * REGENERON PHARMACEUTICALS INC SAYS SAFETY PROFILE IN STUDY WAS GENERALLY CONSISTENT WITH APPROVED ANTI-PD-1 AGENTS.

  • More trends:

    Regulus Therapeutics Inc.RGLS | Reis, IncREIS | Reliv'' International, Inc.RELV | Relypsa, Inc.RLYP | Remark Media, Inc.MARK | Remy International, Inc.REMY | Renasant CorporationRNST | Renewable Energy Group, Inc.REGI | Rent-A-Center Inc.RCII | Rentech, Inc.RTK |